Vaccine manufacturers should be liable for serious vaccine injuries

Debate continues over whether vaccine manufacturers be liable for serious vaccine injuries.

Overview Debates Related claims Topics

Insurers should be barred from setting premiums using genetic tests

The European Commission opened an antitrust investigation into Sanofi's flu vaccine marketing practices

Traditional flu vaccine production relies on egg-based manufacturing with a six-month timeline

mRNA platform technology enables faster vaccine development cycles compared to traditional egg-based production

The FDA approved Moderna's mFlusiva as the first mRNA-based flu vaccine in the United States

mRNA vaccines were first deployed at scale during the COVID-19 pandemic

The UK approved the first trial of a Moderna-Oxford mRNA vaccine to prevent Lynch Syndrome cancers

mRNA vaccine technology was rushed to market without adequate long-term safety data — debated regarding the balance between rapid innovation and comprehensive safety monitoring

Seasonal flu vaccines may reduce severity of H5N1 bird flu infections in humans

GSK advanced its mRNA flu vaccine to late-stage trials after strong mid-stage results

India administered 8 million HPV vaccine doses in six months since its national campaign launch

VAERS receives tens of thousands of reports annually, though most are not confirmed as vaccine-caused

RFK Jr. posted vaccine misinformation amid Pennsylvania measles deaths

Vaccine misinformation has been identified by the WHO as a top global health threat

Utah became a measles epicenter as outbreaks spread statewide amid growing vaccine skepticism

Kennedy reportedly asked the CDC to remove Pennsylvania measles deaths from the official tally

Trump demanded drug companies split combined vaccines following Kennedy's remarks

The National Vaccine Injury Compensation Program has paid over $4 billion in compensation since 1988

RFK Jr. has a long history of vaccine skepticism through the Children's Health Defense organization

Vaccine injury reporting systems are inadequate and undercount adverse events — debated regarding the design of passive surveillance systems versus active safety monitoring